Please use this identifier to cite or link to this item: https://scidar.kg.ac.rs/handle/123456789/14974
Title: Galectin 3 (LGALS3) Gene Polymorphisms Are Associated with Biochemical Parameters and Primary Disease in Patients with End-Stage Renal Disease in Serbian Population
Authors: Kovacevic Z.
Lazarevic, Tatjana
Maksimović N.
Grk M.
Volarevic, Vladislav
Jankovic M.
djukic, aleksandar
Janicijevic K.
Kovačević, Miloš
Ljujic, Biljana
Issue Date: 2022
Abstract: Galectin 3 plays a significant role in the development of chronic renal failure, particularly end-stage renal disease (ESRD). The aim of our study was to investigate the association between Gal-3 and biochemical parameters and primary disease in ESRD patients, by exploring the polymorphisms LGALS3 rs4644, rs4652, and rs11125. A total of 108 ESRD patients and 38 healthy controls were enrolled in the study. Genotyping of LGALS3 gene rs4644, rs4652, and rs11125 polymorphisms was performed by polymerase chain reaction–restriction fragment length polymorphism (PCR–RFLP). By multivariate logistic regression analysis, we found that LGALS3 rs4644 CC and rs4652 AA genotypes were significantly associated with a higher risk for lower hemoglobin, higher level of parathyroid hormone, and also occurrence of diabetes mellitus and arterial hypertension. The CAA haplotype was significantly more common in patients with diabetes, low hemoglobin level, and normal PTH level. It has been observed as well that the ACT haplotype was more common in patients with low glomerular filtration, low PTH, and normal hemoglobin level. We found that the LGALS3 rs4644 and rs4652 gene polymorphism may be involved in the pathogenesis and appearance of complications in ESRD patients and thus could be considered a new genetic risk factor in this population.
URI: https://scidar.kg.ac.rs/handle/123456789/14974
Type: article
DOI: 10.3390/jcm11133874
SCOPUS: 2-s2.0-85133244351
Appears in Collections:Faculty of Medical Sciences, Kragujevac

Page views(s)

392

Downloads(s)

29

Files in This Item:
File Description SizeFormat 
10.3390-jcm11133874.pdf624.67 kBAdobe PDFThumbnail
View/Open


This item is licensed under a Creative Commons License Creative Commons